Skip to main content
OpenTrials
Completed

NCT Number: NCT01024192

Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) in Patients With Chronic insomNIA

Primary Objective:

To evaluate the efficacy and safety of the use of Stilnox CR in Mexican patients with chronic insomnia at the prescription conditions of daily practice

Secondary Objective:

To evaluate the satisfaction of the patient with chronic insomnia with Stilnox CR over an as needed basis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Sanofi-Aventis Administrative Office

Col. Coyoacan, Mexico

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Primary insomnia diagnosis (difficulty for initiating sleep, or maintaining sleep to wake up to early in the morning, or to present a restless sleep) which causes clinically significant disturbances in the areas of social, work functioning or other important areas

Exclusion criteria

  • Serious, severe and/or acute respiratory impairment
  • Severe liver impairment
  • Hypersensitivity to the formulation components or to some of its active metabolites
  • Pregnant or breast-feeding women Patients with important associated disorders in SNC and specially psychotic disorders
  • Patients with the probability of using alcoholic beverages concomitantly (as a precaution measure)
  • Chronic use of benzodiazepines

Moreover, in order to follow the international regulations in terms of the use and handling of hypnotic compounds, and to guarantee the appropriate study performance, no patients with one or more of the following characteristics should be included:

  • Patients who cannot comply to follow-up
  • Patients who have any drug abuse problem
  • Individuals who work changing night shifts or with pathological snoring
  • Presence (or suspicion) of sleep apnea, periodical legs movements or restless legs syndrome

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Treatment and study plan

ZOLPIDEM SL800750

Drug

Pharmaceutical form: Zopidem 12.5 mg tablets

Route of administration: Oral

Dose regimen:One tablet at bed time and as needed (the patients choose which night they take the tablet without limit of number of nights)

Primary outcomes

  1. Improvement of the Clinical Global Impression (CGI) score

    Time frame: At day 84 (visit 5)

Secondary outcomes

  1. Illness severity and average change during the study

    Time frame: At day 1 (baseline), day 14 (visit 2), day 28 (visit 3), day 56 (visit 4) and day 84 (visit 5)

  2. Pittsburgh Sleep Quality Index (PSQI) score

    Time frame: At day 1 (baseline), day 28 (visit 3), day 56 (visit 4) and day 84 (visit 5)

  3. Patient satisfaction questionnaire

    Time frame: At day 84 (visit 5)

  4. Safety evaluation via Adverse events reported

    Time frame: At day 14 (visit 2), day 28 (visit 3), day 56 (visit 4) and day 84 (visit 5)

Sponsors and collaborators

Lead sponsor

Sanofi

Industry

Registry information

Official study title

Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) Administered on as Needed Basis in Patients With Chronic insomNIA

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Dec 2, 2009
Registry last updated
Oct 5, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.